Gilead Sciences, Inc. (GILD) Presents at Baird Global Healthcare Conference 2025

Core Insights - Kite, a subsidiary of Gilead, focuses on cell therapy and has made significant advancements in this field, particularly with its product Yescarta, which has exceeded commercial expectations [2]. Company Overview - Kite was acquired by Gilead nearly a decade ago, and this acquisition has played a crucial role in its development and success in the biotech industry [2]. - The company is currently generating exciting data from several late-stage programs, indicating a strong pipeline and potential for future growth [2].